Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 20/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 19/20 | 0.58 |
| ▸ | DRD2 | P14416 | 17/20 | 0.58 |
| ▸ | DRD4 | P21917 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13312911 | 0.87 | DRD3 (0.57) | DRD3KCNH2DRD2CYP1A2CYP2C19 | |
| SCHEMBL13312912 | 0.84 | DRD3 (0.46) | DRD3KCNH2DRD2DRD4CYP1A2 | |
| SCHEMBL3550786 | 0.84 | DRD3 (0.46) | DRD3KCNH2DRD2DRD4CYP1A2 | |
| SCHEMBL378254 | 0.79 | DRD3 (0.57) | DRD3KCNH2DRD2DRD4CYP1A2 | |
| SCHEMBL14567285 | 0.79 | DRD3 (0.57) | DRD3KCNH2DRD2DRD4CYP1A2 | |
| SCHEMBL1414722 | 0.79 | DRD3 (0.57) | DRD3KCNH2DRD2DRD4CYP1A2 | |
| SCHEMBL919050 | 0.79 | DRD3 (0.55) | DRD3KCNH2DRD2DRD4CYP1A2 | |
| SCHEMBL3557525 | 0.78 | DRD3 (0.58) | DRD3KCNH2DRD2DRD4CYP1A2 | |
| Hydrochloric Acid SCHEMBL3548416 | 0.77 | DRD3 (0.57) | DRD3KCNH2DRD2DRD4CYP1A2 | |
| SCHEMBL14606076 | 0.77 | DRD3 (0.55) | DRD3KCNH2DRD2DRD4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745458-B2 | Azabicyclo (3, 1, 0) hexan derivatives useful as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-20090221618-A1 | AZABICYCLO (3, 1, 0) HEXAN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221618-A1 | AZABICYCLO (3, 1, 0) HEXAN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | HTR5A, CHRNA5, DRD3 | DRD3 3/4885KCNH2 464/4885DRD2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.